Ceradyne Stock Hits New 52-Week High (CRDN)

NEW YORK ( TheStreet) -- Ceradyne (Nasdaq: CRDN) hit a new 52-week high Monday as it traded at $46.62 compared with its previous 52-Week high of $46.60. Ceradyne is changing hands at $46.62 with 12,518 shares traded as of 9:35 a.m. ET. Average volume has been 249,400 shares over the past 30 days.

Ceradyne has a market cap of $1.1 billion and is part of the industrial goods sector and industrial industry. Shares are up 45.2% year to date as of the close of trading on Friday.

Ceradyne, Inc. engages in the development, manufacture, and marketing of technical ceramic products, ceramic powders, and components for defense, industrial, automotive/diesel, and commercial applications in the United States and internationally. The company has a P/E ratio of 39.2, equal to the average industrial industry P/E ratio and above the S&P 500 P/E ratio of 16.3.
  • Practice your CRDN trading strategies and win cash in our stock game.

TheStreet Ratings rates Ceradyne as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full Ceradyne Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

null

More from Markets

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Global Stocks Rally as US-China Trade War Thaws; Dow Could Test 25,000

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)